BRAFm+ Metastatic melanoma
What makes it different, makes it vulnerable

BRAF inhibitors

Targeting the MAP kinase pathway

For patients with unresectable or metastatic melanoma and a confirmed BRAF V600 mutation there are currently several licensed treatment options available; these include targeted agents, which work directly on the oncogenic driver by targeting the MAP kinase pathway, through BRAF or MEK inhibition.

BRAF and MEK inhibition target the MAP kinase pathway1,2

 

  1. Inamdar GS, et al. Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail. Biochem Pharmacol. 2010;80(5):624-37.
  2. Paluncic J, et al. Roads to melanoma: key pathways and emerging players in melanoma progression and oncogenic signaling. Biochim Biophys Acta. 2016;1863(4):770-84.